10 reasons why to prescribe statin with ezetimibe Review article
Article Sidebar
Published:
Sep 30, 2018
Keywords:
dyslipidemia, multidrug therapy, ezetimibe
Main Article Content
Abstract
Dyslipidemia is still one of the most important risk factor of cardiovascular diseases. In theory it can be modified, in true clinical practice however the efficacy of the treatment is still far from being perfect. According to guidelines we should use strong statins in maximal tolerated doses. Goals of LDL reduction are however lower than few years ago and even atorvastatin or rosuvastatin can be not enough to reach them. By adding ezetimibe we can not only reach the LDL goal, but also improve cardiovascular outcomes. In the article we give you 10 reasons why to use statin and ezetimibe together.
Article Details
How to Cite
Wełnicki , M., Janiszewski , M., & Mamcarz , A. (2018). 10 reasons why to prescribe statin with ezetimibe. Medycyna Faktow (J EBM), 11(3(40), 176-181. https://doi.org/10.24292/01.MF.0318.2
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Wytyczne ESC/EAS dotyczące leczenia zaburzeń lipidowych w 2016 roku Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) i Europejskiego Towarzystwa Miażdżycowego (EAS) do spraw leczenia zaburzeń lipidowych. Dokument opracowano przy szczególnym udziale European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Kardiol. Pol. 2016; 74(11): 1234-1318.
2. Sliż D., Filipiak K.J., Naruszewicz M. et al.: Standards of statin usage in Poland in high-risk patients: 3ST-POL study results. Kardiol. Pol. 2013; 71(3): 253-259.
3. Wełnicki M., Folga A., Sudoł K., Mamcarz A.: Efficacy of hypercholesterolemia treatment in Poland-Analysis of the CEPHEUS study results. Pol. Przegl. Kardiol. 2014; 16(1): 5-11.
4. Giugliano R.P., Cannon C.P., Blazing M.A. et al.; on behalf of the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators: Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT. Circulation 2017 [Epub ahead of print].
5. Pasierski T.: Ezetymib – lek stwarzający nowe możliwości obniżenia stężenia cholesterolu. Folia Cardiologica Excerpta 2009; 4(supl. A).
6. Pikto-Pietkiewicz W., Pasierski T.: Ezetymib – inhibitor wchłaniania cholesterolu. Kardiol. Pol. 2006; 64: 1434-1441.
7. Knopp R.H., Dujovne C.A., Le Beaut A. et al.: Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int. J. Clin. Pract. 2003; 57: 363-368.
8. Ballantyne C.M., Houri J., Notarbartolo A. et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415.
9. Davidson M.H., McGarry T., Bettis R. et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 2002; 40: 2125-2134.
10. Melani L., Mills R., Hassman D. et al.: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur. Heart J. 2003; 24: 717-728.
11. Kerzner B., Corbelli J., Sharp S. et al.: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 2003; 91: 418-424.
12. Davidson M.H., Ballantyne C.M., Kerzner B. et al.: Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract. 2004; 58: 746-755.
13. Baigent C., Landray M.J., Reith C. et al.; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-2192.
14. Giugliano R.P., Wiviott S.D., Blazing M.A. et al.: Long-Term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017; 2: 547-555.
15. Eisen A., Cannon C.P., Blazing M.A. et al.: The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur. Heart J. 2016; 37: 3576-3584.
16. Ferreira A.M., Marques da Silva P.: Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. Am. J. Cardiovasc. Drugs 2017; 17(3): 169-181.
2. Sliż D., Filipiak K.J., Naruszewicz M. et al.: Standards of statin usage in Poland in high-risk patients: 3ST-POL study results. Kardiol. Pol. 2013; 71(3): 253-259.
3. Wełnicki M., Folga A., Sudoł K., Mamcarz A.: Efficacy of hypercholesterolemia treatment in Poland-Analysis of the CEPHEUS study results. Pol. Przegl. Kardiol. 2014; 16(1): 5-11.
4. Giugliano R.P., Cannon C.P., Blazing M.A. et al.; on behalf of the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators: Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT. Circulation 2017 [Epub ahead of print].
5. Pasierski T.: Ezetymib – lek stwarzający nowe możliwości obniżenia stężenia cholesterolu. Folia Cardiologica Excerpta 2009; 4(supl. A).
6. Pikto-Pietkiewicz W., Pasierski T.: Ezetymib – inhibitor wchłaniania cholesterolu. Kardiol. Pol. 2006; 64: 1434-1441.
7. Knopp R.H., Dujovne C.A., Le Beaut A. et al.: Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int. J. Clin. Pract. 2003; 57: 363-368.
8. Ballantyne C.M., Houri J., Notarbartolo A. et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415.
9. Davidson M.H., McGarry T., Bettis R. et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 2002; 40: 2125-2134.
10. Melani L., Mills R., Hassman D. et al.: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur. Heart J. 2003; 24: 717-728.
11. Kerzner B., Corbelli J., Sharp S. et al.: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 2003; 91: 418-424.
12. Davidson M.H., Ballantyne C.M., Kerzner B. et al.: Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract. 2004; 58: 746-755.
13. Baigent C., Landray M.J., Reith C. et al.; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-2192.
14. Giugliano R.P., Wiviott S.D., Blazing M.A. et al.: Long-Term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017; 2: 547-555.
15. Eisen A., Cannon C.P., Blazing M.A. et al.: The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur. Heart J. 2016; 37: 3576-3584.
16. Ferreira A.M., Marques da Silva P.: Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. Am. J. Cardiovasc. Drugs 2017; 17(3): 169-181.